From Target to Lead Synthesis

Proteomics in Drug Research

Volumn , Issue , 2006, Pages 187-207

  Müllner, Stefan ^a   Stark, Holger ^b   Niskanen, Päivi ^b   Eigenbrodt, Erich ^c   Mazurek, Sybille ^c   Fasold, Hugo ^b  

^a PROTAGEN AG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Affinity chromatography; Cells and culture conditions; Drug research; Electrophoresis and protein identification; In vitro activity testing; Materials; Methods; Proteomics

Indexed keywords

AFFINITY CHROMATOGRAPHY; DISEASES; ELECTROPHORESIS; MATERIALS; MOLECULAR BIOLOGY;

CULTURE CONDITIONS; DRUG RESEARCH; IN-VITRO; METHODS; PROTEIN IDENTIFICATION; PROTEOMICS;

LEAD COMPOUNDS;

EID: 84857176037     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608230.ch10     Document Type: Chapter

References (73)

1. Abe, H., Obinata, T., Minamide, L. S., Bamburg, J. R. (1996). Xenopus laevis actin-depolymerizing factor cofilin: a phophorylation-regulated protein essential for development. J. Cell Biol. 132, 871-885.
2. Ashizawa, K., Willingham, M. C., Liang, C. M., Cheng, S. Y. (1991). In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-biphosphate. J. Biol. Chem. 266, 16842-16846.
3. Bahl, A. K., Dale, M. M., Foreman, J. C. (1994). The effect of non-steroidal anti-inflammatory drugs on the accumulation and release of interleukin-1-like activity by peritoneal macrophages from the mouse. Br. J. Pharmacol. 113, 809-814.
4. Bartlett, R. R., Dimitrijevic, M., Mattar, T., Zielinski, T., Germann, T., Ruede, E., Thoenes, G. H., Küchle, C. C. A., Schorlemmer, H. U., Bremer, E., Finnegan, A., Schleyerbach, R. (1991). Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 31(1/2), 10-21.
5. Breedveld, F. C., Dayer, J. M. (2000). Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 59, 841-849.
6. Burger, D., Begue-Pastor, N., Benavent, S., Gruaz, L., Kaufmann, M. T., Chicheportiche, R., Dayer, J. M. (2003). The active metabolite of Leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 42, 89-96.
7. Cao, W. W., Kao, P. N., Chao, A. C., Gardner, P., Ng, J., Morris, R. E. (1995). Mechanism of the antiproliferative action of Leflunomide. A77 1726, the active metabolite of Leflunomide does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. J. Heart Lung Transplant. 14, 1016-1030.
8. Cherwinski, H. M., Byars, N., Ballaron, S. J., Nakano, G. M., Young, J. M., Ransom, J. T. (1995). Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm. Res. 44, 317-322.
9. Craig, E. A. (1993). Chaperones: helpers along the pathways to protein folding. Science 260, 1902-1903.
10. Dax, C. I. (1996). Proteinchemisch Methoden zur Identifizierung und Charakterisierung entzündungsrelevanter Polypeptide. PhD Thesis, University of Frankfurt/M., Germany.
11. Dax, C. I., Lottspeich, F., Müllner, S. (1998). in vitro model system for the identification and characterization of proteins involved in inflammatory processes. Electrophoresis 19, 1841-1847.
12. Deage, V., Burger, D., Dayer, J. M. (1998). Exposure of T lymphocytes to Leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases. Eur. Cytokine Netw. 9, 663-668.
13. Edwards, K. A., Montague, R. A., Shepard, S., Edgar, B. A., Erikson, R. L., Kiehart, D. P. (1994). Identification of Drosophila cytoskeletal proteins by induction of abnormal cell shape in fission yeast. Proc. Natl. Acad. Sci. USA 91, 4589-4593.
14. Eigenbrodt, E., Gerbracht, U., Mazurek, S., Presek, P., Friis, R. (1994). Carbohydrate metabolism and neoplasia: New perspectives for diagnosis and therapy. Biochem. Mol. Aspects Sel. Cancers 2, 311-385.
15. Eigenbrodt, E., Kallinowski, F., Ott, M., Mazurek, S., Vaupel, P. (1998). Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer Res. 18, 3267-3274.
16. Elder, R. T., Xu, X., Williams, J. W., Gong, H., Finnegan, A., Chong, A. S. (1997). The immunosuppressive meta-bolite of Leflunomide, A77 1726 affects murine T cells through two biochemical mechanisms. J. Immunol. 159, 22-27.
17. Emery, P., Breedveld, F. C., Lemmel, E. M., Kaltwasser, J. P., Dawes, P. T., Gomor, B., Van Den Bosch, F., Nordstrom, D., Bjorneboe, O., Dahl, R., Horslev-Petersen, K., Rodriguez De La Serna, A., Molloy, M., Tikly, M., Oed, C., Rosenburg, R., Loew-Friedrich, I. (2000). A comparison of the efficacy and safety of Leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39, 655-665.
18. Fairbanks, L. D., Bofill, M., Ruckemann, K., Simmonds, H. A. (1995). Importance of ribonucleotide availability to proliferating T-Lymphocytes from healthy humans. J. Biol. Chem. 270, 29682-29689.
19. Feldmann, M., Brennan, F. M., Maini, R. N. (1996). Rheumatoid arthritis. Cell 85, 307-310.
20. Gessani, S., Testa, U., Varano, B., DiMarzio, P., Borghi, P., Conti, L., Barbed, T., Tritarelle, E., Martucci, R., Seripa, D., Peschle, C., Belardelli, F. (1993). Enhanced production of LPS-induced cytokines during differentiation of human monocytes to macrophages. Role of LPS receptors. J. Immunol. 151, 3758-3766.
21. Gunsalus, K. C., Bonaccorsi, S., Williams, E., Verni, F., Gatti, M., Goldberg, M. L. (1995). Mutations in twinstar, a DrosIophila gene encoding a cofilin/ADF homologue, result in defects in centrosome migration and cytokinesis. J. Cell Biol. 131, 1243-1259.
22. Hacker, H. J., Steinberg, P., Bannasch, P. (1998). Pyruvate kinase isoenzyme shift from l-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/dl-ethionine-supplement diet. Carcinogenesis 19, 99-107.
23. Hamilton, L. C., Vojnovic, I., Warner, T. D. (1999). A77 the active metabolite of Leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br. J. Pharmacol. 127, 1589-1596.
24. Herrmann, M. L., Schleyerbach, R., Kirschbaum, B. J. (2000). Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 47, 273-289.
25. Heukeshoven, J., Dernick, R. (1985). Simplified method for silver staining of proteins in polyacrylamide gels and the mechanism of silver staining. Electrophoresis 6, 103-112.
26. Hünig, S., Schaller, R. (1982). Zur Chemie der Acylcyanide. Angew. Chem. Int. Ed. Engl. 21, 36-49.
27. Ishii, T., Yamada, M., Sato, H., Matsue, M., Taketani, S., Nakayama, K., Sugita, Y., Bannai, S. (1993). Cloning and characterization of a 23-kDa stress-induced mouse peritoneal macrophage protein. J. Biol. Chem. 268, 18633-18636.
28. Kane, C. D., Coe, N. R., Vanlandingham, B., Krieg, P., Bernlohr, D. A. (1996). Expression purification, and ligand-binding analysis of recombinant keratinocyte lipid-binding protein (MAL-1), an intracellular lipid-binding found overexpressed in neoplastic skin cells. Biochemistry 35, 2894-2900.
29. Kawai, S., Takeshita, S., Okazaki, M., Kikuno, R., Kudo, A., Amann, E. (1994). Cloning and characterization of OSF-3, a new member of the MER5 family, expressed in mouse osteoplasmatic cells. J. Biochem. 115, 641-643.
30. Kirchner, H., Kruse, A., Neustock, P., Rink, L. (1996). Cytokine and Interferone. Spektrum Akademischer Verlag, Heidelberg.
31. Kirschbaum, B., Müllner, S., Bartlett, R. (1999). DEAH-Box Proteins. US Patent 5,942,429.
32. Knecht, W., Bergjohann, U., Gonski, S., Kirschbaum, B., Loeffler, M. (1996). Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme. Eur. J. Biochem. 240, 292-301.
33. Koyasu, S., Nishida, E., Kadowaki, T., Matsuzaki, F., Iida, K., Harada, F., Kasuga, M., Sakai, H., Yahara, I., (1989). Two mammalian heat shock proteins, HSP90 and HSP100, are actin-binding proteins. Proc. Natl. Acad. Sci. USA, 83, 8054-8058.
34. Krieg, P., Feil, S., Furstenberger, G., Bowden, G. T. (1993). Tumor specific overexpression of a novel keratinocyte lipid-binding protein. Identification and characterization of a cloned sequence activated during multistage carcino-genesis in mouse skin. J. Biol. Chem. 268, 17362-17369.
35. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
36. Lappalainen, P., Drubin, D. G. (1997). Cofilin promotes rapid actin filament turnover in vivo. Nature 388, 78-82.
37. Lindquist, S. (1986). The heat shock response. Ann. Rev. Biochem. 55, 1151.
38. Mangold, U., Dax, C. I., Saar, K., Schwab, W., Kirschbaum, B., Müllner, S. (1999). Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune disease. Eur. J. Biochem. 266, 1184-1191.
39. Manna, S. K., Aggarwal, B. B. (1999). Immunosuppressive Leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J. Immunol. 162, 2095-2102.
40. Manna, S. K., Mukhopadhyay, A., Aggarwal, B. B. (2000). Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J. Immunol. 165, 5962-5969.
41. Mattar, T., Kochhar, K., Bartlett, R., Bremer, E. G., Finnegan, A. (1993). Inhibition of the epidermal growth factor receptor tyrosine kinase activity by Leflunomide. FEBS Lett. 334, 161-164.
42. Mazurek, S., Grimm, H., Wilker, S., Leib, S., Eigenbrodt, E. (1998). Metabolic characteristics of different malignant cancer cell lines. Anticancer Res. 18, 3275-3282.
43. Mazurek, S., Eigenbrodt, E. (2003). The tumor metabolome. Anticancer Res. 23, 1149-1154.
44. Mazurek, S., Eigenbrodt, E., Failing, K., Steinberg, P. (1999). Alterations in the glycolytic and glutaminolytic pathways after malignant transformation of rat liver oval cells. J. Cell Physiol. 181, 136-146.
45. Méjean, C., Pons, F., Benyamin, Y., Roustan, C. (1989). Antigenic probes locate binding sites for the glycolytic enzymes glyceralehyde-3-phosphate dehydrogenase, aldolase and phosphofructokinase on the actin monomer in microfilaments. Biochem. J. 264, 671-677.
46. Müller, E., Badel, K., Müller, A., Herbert, S., Seiler, A. (1993). Offenlegungsschrift DE 43 10 964 A1: Aktivierte Trägermaterialien, ihre Herstellung und Verwendung. Deutsches Patentamt.
47. Müllner, S., Eigenbrodt, E. (2001). 1-Butyric acid derivatives such as carbomethoxypropionyl cyanide or Leflunomide derivatives and the therapeutic use thereof. European Patent Application (EP 1 377 291).
48. Ortlepp, D., Laggerbauer, B., Müllner, S., Achsel, T., Kirschbaum, B., Lührmann, R. (1998). The mammalian homologue of Prp16p is overexpressed in a cell line tolerant to Leflunomide, a new immunoregulatory drug effective against rheumatoid arthritis. RNA 4, 1007-1018.
49. Pejovic, M., Stankovic, A., Mitrovic, D. R. (1992). Lactate dehydrogenase activity and its isoenzymes in serum and synovial fluid of patients with rheumatoid arthritis and osteoarthritis. J. Rheumatol. 19, 529-533.
50. Samstag, Y., Dreizler, E. M., Ambach, A., Sczakiel, G., Meuer, S. C. (1996). Inhibition of constitutive serine phosphate activity in T lymphoma cells result in phosphorylation of pp19/cofilin and induces apoptosis. J. Immunol. 156, 4167-4173.
51. Samstag, Y., Eckerskorn, C., Wesselborg, S., Henning, S., Wallich, R., Meuer, S. C. (1994). Costimulatory signals for human T-cell activation induce nuclear translocation of pp19/cofilin. Proc. Natl. Acad. Sci. USA 91, 4494-4498.
52. Schreiber, S. L., Crabtree, G. R. (1992). The mechanism of action of cylosporin A and FK506. Immunol. Today 13, 136-142.
53. Shau, H., Butterfield, L. H., Chiu, R., Kim, A. (1994). Cloning and sequence analysis of candidate human natural killer-enhancing factor genes. Immunogenetics 40, 129-134.
54. Siemasko, K. F., Chong, A. S., Williams, J. W., Bremer, E. G., Finnegan, A. (1996). Regulation of B cell function by the immunosuppressive agent Leflunomide. Transplantation 61, 635-642.
55. Silva, H. T., Cao, W., Shorthouse, R. A., Morris, R. E. (1996). Mechanism of action of Leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation. Transplant. Proc. 28, 3082-3084.
56. Silva, H. T., Cao, W., Shorthouse, R. A., Loffler, M., Morris, R. E. (1997). in vitro and in vivo effects of Leflunomide, Brequinar and Cyclosporine on pyrimidine biosynthesis. Transplant. Proc. 29, 1292-1293.
57. Smith, A. B., Fukui, M., Vaccaro, H. A., Empfield, J. R. (1991). Phyllanthosidephyllanthostatin synthetic studies. 7. Total synthesis of (+)-Phyllanthocin and (+)-Phyllanthocindiol. J. Am. Chem. Soc. 113, 2071-2092.
58. Smolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-Friedrich, I., Oed, C., Rosenburg, R. (1999). Efficacy and safety of Leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multi-centre trial. Lancet 353, 259-266.
59. Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G., Fox, R., Moreland, L., Olsen, N., Furst, D., Caldwell, J., Kaine, J., Sharp, J., Hurley, F., Loew-Friedrich, I. (1999). Treatment of active rheumatoid arthritis with Leflunomide compared with placebo and methotrexate. Arch. Intern. Med. 159, 2542-2550.
60. Stoscheck, C. M. (1990). Quantitation of Protein Methods in Enzymology. Pierce, Rockford, IL, USA, 182, 50-69.
61. Suzuki, K., Yamaguchi, T., Tanaka, T., Kawanishi, T., Nishimaki-Mogami, T., Yamamoto, K., Tsuji, T., Irimura, T., Hayakawa, T., Takahashi, A. (1995). Activation induces dephosphorylation of cofilin and its translocation to plasma membranes in neutrophil-like differentiated HL-60 cells. J. Biol. Chem. 270, 19551-19556.
62. Tang, Q., Sen, S. E. (1998). Carbomethoxypropionyl cyanide: a regioselective C-acylation reagent for the preperation of β-dicarbonyl compounds. Tetrahedron Lett. 39, 2249-2252.
63. Vyse, T. J., Todd, J. A. (1996). Genetic analysis of autoimmune disease. Cell 85, 311-318.
64. Wen, S.-T., Van Etten, R. A. (1997). The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 11, 2456-2467.
65. Williamson, R. A., Yea, C. M., Robson, P. A., Curnock, A. P., Gadher, S., Hambleton, A. B., Woodward, K., Bruneau J-M, Hambleton, P., Moss, D., Thomson, T. A., Spinella-Jaegle, S., Morand, T., Courtin, O., Sautés, C., Westwood, R., Hercend, T., Kuo, E. A., Ruuth, E. (1995). Dihydroorotate dehydrogenase is a high-affinity binding protein of A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. 270, 22467-22472.
66. Williamson, R. A., Yea, C. M., Robson, P. A., Curnock, A. P., Gadher, S., Hambleton, A. B., Woodward, K., Bruneau, J. M., Hambleton, P., Spinella-Jaegle, S., Morand, P., Courtin, O., Sautes, C., Westwood, R., Hercend, T., Kuo, E. A., Ruuth, E. (1996). Dihydroorotate dehydrogenase is a target for the biological effects of Leflunomide. Transplant. Proc. 28, 3088-3091.
67. Winfield, J., Jarjour, W. (1991). Do stress proteins play a role in arthritis and auto-immunity? Immunol. Rev. 121, 121-220.
68. Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J., Mathison, J. C. (1990). CD 14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249, 1431-1433.
69. Wu, Y. W., Chik, C. L., Knazek, R. A. (1989). An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res. 49, 3754-3758.
70. Xu, X., Williams, J. W., Gong, H., Finnegan, A., Chong, A. S. (1996). Two activities of the immunosuppressive metabolite of Leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem. Pharmacol. 52, 527-534.
71. Yilmaz, S., Ozan, S., Ozercan, I. H. (2003). Comparison of pyruvate kinase variants from breast tumor and normal breast. Arch. Med. Res. 34, 315-324.
72. Zielinski, T., Zeitter, D., Muller, S., Bartlett, R. R. (1995). Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? Inflamm. Res. [Suppl. 2], S207-208.
73. Zwerschke, W., Mazurek, S., Massimi, P., Banks, L., Eigenbrodt, E., Jansen-Durr, P. (1999) Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA 96, 1291-1296.